Navigation Links
Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the People's Republic of China
Date:3/27/2008

Acquisition Expected to Add New Drug Products to Aida Pharmaceuticals,

Inc.'s Product Line

SANTA MONICA, Calif., March 27 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that it has signed two share transfer agreements to acquire a controlling interest in one of the leading microbiology research institutes in the People's Republic of China, Jiangsu Institute of Microbiology Co., Ltd. ("JSIM"). Aida Pharmaceutical's subsidiary, Hangzhou Aida Pharmaceuticals Co., Ltd. will be acquiring a 43% equity interest in JSIM from Jin'ou Medicine Co., Ltd. while Aida Pharmaceutical's other subsidiary, Changzhou Fangyuan Pharmaceutical Co., Ltd. will be acquiring a 55% equity interest in JSIM from Jiangyin Hi-tech Group. The transaction is expected to close shortly. After the completion of the acquisition, Jiangsu Institute of Microbiology Co., Ltd. will become an indirect subsidiary of Aida Pharmaceuticals. This acquisition is expected to add several new products to Aida Pharmaceutical's existing line of products, including several drugs that are undergoing clinical trials by the PRC's State Food and Drug Administration.

Mr. Jin Biao, Chairman and CEO of Aida Pharmaceuticals, noted, "We believe this acquisition will significantly strengthen the research resources of Aida Pharmaceuticals. We are proud to have JSIM join our group of companies and I believe the acquisition will fortify our mission to be an innovative pharmaceutical company in the People's Republic of China."

Jiangsu Institute of Microbiology Co., Ltd. is a national leader in microbiology with over thirty years of research history. JSIM, located in Wuxi City in Jiangsu Province, has over thirty scientists and engineers that have completed over 200 research projects. Over twenty research projects were developed as national-level key projects, as designated by the Chinese government. JSIM's research efforts have yielded numerous patents.

About Aida Pharmaceuticals, Inc.

Aida Pharmaceuticals, Inc. is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, People's Republic of China with manufacturing, distribution and sales points throughout mainland China. Aida Pharmaceuticals, Inc. is GMP-certified in the People's Republic of China and ISO9002-certified for quality assurance and ISO14000 certified for ecologically-friendly practices.

For additional information, please visit http://en.aidapharma.com .

Contact Information:

Ashley Hull

(310) 450-9100 opt 1

ashley@leacapital.com

Broker Contact:

Chesapeake Group

(410) 825-3930

Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.


'/>"/>
SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
2. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
3. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
4. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
5. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
6. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
9. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
10. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
11. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... The new and improved Oakton® pocket testers, from ... stand upright with a new cap design that is versatile, functional and leakproof. They ... need to test water quality. , The Oakton pocket testers have many user-friendly and ...
(Date:9/19/2017)... 2017 ValGenesis Inc., the global leader in ... announce the strategic partnership with VTI Life Sciences (VTI). ... services using the latest technology available in the ValGenesis ... with efficient and cost-effective validation services using ValGenesis VLMS. ... ValGenesis VLMS system. ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North ... to isolate single cells and provide visual documentation of monoclonality for use in ...
(Date:9/19/2017)... Charlotte, NC (PRWEB) , ... September 19, 2017 ... ... focusing on band technologies for surgical applications, announced today that two new patents ... System. , Michael Albert, MD, Co-Founder of Band-LOK, said, “We continue to explore ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):